9th Korea-Japan Gynecologic Cancer Joint Meeting by Ryu, Hee-Sug & Sugiyama, Toru
Since the 1st Korea-Japan Gynecologic Cancer Joint Meeting 
in Seoul, October 22, 2002 during 9th International Gyneco-
logic Cancer Society meeting, Gynecologic Cancer Joint Meet-
ings have been held alternatively in Korea and Japan every 
year until 8th meeting in Tokyo in 2009. From the 9th meeting 
of this year on, Gynecologic Cancer Joint Meetings between 
Japan and Korea are supposed to be held every other year at 
the same period of time as biennial meeting of Asian Society 
of Gynecologic Oncology (ASGO). The 9th Korea-Japan Gyne-
cologic Cancer Joint Meeting was held in Seoul on November 
3, 2011 during 2nd biennial meeting of ASGO (Fig. 1). The 
agenda of the meeting is shown in Table 1.
DISCUSSION AND FUTURE PERSPECTIVES
There are several trials proposed by Korean Gynecologic On-
cology Group (KGOG). Two trials of cervical cancer were initi-
ated by Dr. Sang Young Ryu, GOG 263, and TACO trial. GOG 
263 is a randomized phase III trial of adjuvant radiation versus 
chemoradiation in intermediate risk, stage I/IIA cervical cancer 
treated with initial radical hysterectomy and pelvic lymphad-
enectomy. TACO (GCIG/KGOG 1027) is a randomized trial of 
weekly versus tri-weekly cisplatin based chemoradiation in 
locally advanced cervical cancer. Dr. Sokbom Kang and Profes-
sor Noriaki Sakuragi collaborated for a cross-validation study 
to develop preoperative criteria identifying for low-risk group 
of lymph node metastasis in endometrial cancer. Regarding 
ovarian cancer, professor Byoung-Gie Kim suggested a trans-
lational research on clear cell carcinoma, which needs consor-
tium of several countries with high prevalence of the disease, 
and sharing of tissue samples and co-work between Japan, 
Taiwan, and Korea. Lastly, future perspectives of this Korea-
Japan Joint meeting include: deepening our friendships, shar-
ing other’s scientific achievements, co-work for mutual clinical 
protocols, developing cancer treatment guidelines together, 
and exchange programs for faculties and residents. I would 
like to express my heartiest gratitude to Japan Gynecologic 
Oncology Group (JGOG) who graciously accepted our invita-
tion to share their expertise in the field of gynecologic oncol-
ogy (presented by Professor Hee-Sug Ryu).
JGOG desires to work together with KGOG more closely 
through this Korea-Japan Gynecologic Cancer Joint Meeting. 
In Korea and Japan, neoadjuvant chemotherapy followed by 
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radical hysterectomy for stage I/II cervical cancer with a bulky 
mass and chemoradiation for advanced disease have been 
important subjects for research (JGOG 1065, KGOG 1029, and 
GOG 263). JGOG 2043, a randomized study on adjuvant che-
motherapy of Paclitaxel/Carboplatin and Docetaxel/Cisplatin 
compared with a control therapy Adriamycin/Cisplatin in en-
dometrial cancer, is in the process of being analyzed. The re-
sults are expected to have a great impact on the management 
of endometrial cancer around the world. In ovarian cancer, we 
have completed an international cooperative phase III study 
of clear cell carcinoma of ovary (JGOG 3017) in cooperation 
with KGOG and expect the analysis results will be presented 
at American Society of Clinical Oncology 3 years later. Another 
clinical trial of ovarian clear cell carcinoma, GOG 268, is now 
underway in full scale. In addition, based on the promising 
result of phase II clinical trial of Olaparib, a phase III clinical trial 
of ovarian cancer for poly (ADP-ribose) polymerase (PARP) in-
hibitor was proposed. Professor Fujiwara remarked our effort 
for the standardization of intraperitoneal chemotherapy in 
ovarian cancer (JGOG 3019/iPocc trial). Finally, we expect the 
ceaseless collaboration between KGOG and JGOG to be much 
closer in the future (presented by Professor Toru Sugiyama).
Table 1. Agenda of 9
th Korea-Japan Gynecologic Cancer Joint Meeting
Opening remarks & introduction
Joo-Hyun Nam (President of KGOG, Univ. of Ulsan) & Kazunori Ochiai (President of JGOG, The Jikei Univ.)
Part 1 Ovary session chaired by Byoung-Gie Kim (Sungkyunkwan Univ.) & Mitsuaki Suzuki (Jichi Medical Univ.)
• KGOG 3022: Multi-center, retrospective study of image-based prediction model for surgical cytoreduction in advanced ovarian cancer, 
Sokbom Kang (National Cancer Center)
• JGOG 3019/iPocc trial: A randomized phase II/III trial of weekly IV versus tri-weekly IP carboplatin both in combination with weekly IV 
paclitaxel for newly diagnosed epithelial ovarian, fallopian tube, and primary peritoneal cancer, Keiichi Fujiwara (Saitama Med Univ. Int Med 
Center)
Part 2 Cervix session chaired by Sang Young Ryu (Korea Cancer Center Hospital) & Mikio Mikami (Tokai Univ.)
• KGOG 1029: A randomized controlled trial comparing radical hysterectomy plus tailored adjuvant therapy versus primary chemoradiation 
therapy in bulky early-stage cervical cancer, Jeong Yeol Park (Univ. of Ulsan) 
• JGOG 1065: The utility of neoadjuvant chemotherapy using irinotecan hydrochloride (CPT-11) and nedaplatin (NDP) for the bulky but 
operable cancer with the uterine cervix, Ken Takizawa (The Cancer Institute Hospital of JFCR)
Part 3 Uterine corpus session chaired by Jae Weon Kim (Seoul National Univ.) & Toshiaki Saito (National Kyushu Cancer Center)
• KGOG 2006: Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective 
multicenter study, Seok-Ju Seong (CHA Univ.)
• Japanese trial: A randomized phase II/III trial of dose-dense weekly paclitaxel plus carboplatin versus tri-weekly paclitaxel plus carboplatin in 
chemo-naive patients with stage I-IV, persistent, or recurrent carcinosarcoma of the uterus, Takeo Otsuki (Tohoku Univ.)
Discussion and future perspectives 
Hee-Sug Ryu (Ajou Univ.) & Toru Sugiyama (Iwate Medical Univ.)
Closing remarks 
Ikuo Konishi (Kyoto Univ.) & Soon-Beom Kang (Seoul National Univ.)